Clinical Trials Directory

Trials / Completed

CompletedNCT00106418

A Research Study for Patients With Prostate Cancer

An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
35 (actual)
Sponsor
Celgene · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the activity of romidepsin (depsipeptide,FK228) in patients with metastatic prostate cancer who have developed a rising prostate specific antigen (PSA) while undergoing hormonal therapy.

Conditions

Interventions

TypeNameDescription
DRUGRomidepsin13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.

Timeline

Start date
2003-05-07
Primary completion
2006-09-01
Completion
2006-09-01
First posted
2005-03-25
Last updated
2019-11-18

Source: ClinicalTrials.gov record NCT00106418. Inclusion in this directory is not an endorsement.